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transferred from one point of care to the next with treatment continuation potentially 
being delayed. 88 providers of care (60 institutions), 30 patients diagnosed with 
schizophrenia and 17 patients diagnosed with depression were surveyed through in-
depth interviews. The total number of questions was 56 for providers, and 54 ques-
tions for patients. RESULTS: A total of 56% of patients diagnosed with schizophrenia 
(mean age 45 years, mean duration of illness 16 years) experience waiting times when 
transferred to an outpatient rehabilitation center, 50% while being transferred to an 
institution of assisted working or to a place of sheltered living (33%). Patients diag-
nosed with major depression (mean age 45 years; mean duration of illness 13 years) 
experience waiting times when transferred to an institution of assisted working (63%), 
to an outpatient rehabilitation center (57%) or to a psychotherapist (56%). Providers 
experience waiting times when they transfer patients to psychotherapists (55%). a 
total of 40% of patients diagnosed with schizophrenia and 58% of patients diagnosed 
with major depression perceive waiting times as heavily constraining, affecting their 
treatment and care, and potentially leading to a setback in their treatment progress. 
Providers see capacity constraints as main reason for waiting times. CONCLUSIONS: 
This study describes waiting times in coordination of mental health care between 
different providers as a problem. Potential negative effects on treatment success show 
the need for optimization. 
MENTAL HEALTH – Conceptual Papers & Research on Methods
PMH70
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OBJECTIVES: The Alcohol Dependence Scale (ADS) is a quantitative measure of the 
severity of alcohol dependence consistent with the concept of the alcohol dependence 
syndrome. The 25 items cover alcohol withdrawal symptoms, impaired control over 
drinking, awareness of a compulsion to drink, increased tolerance to alcohol, and 
salience of drink-seeking behavior. This study aims to adapt the ADS questionnaire 
into Turkish culture and check the reliability and validity of the questionnaire cultur-
ally. METHODS: The original instrument was translated and back translated by two 
independent translators. For psychometric measures, a small sample was used to check 
the initial comprehension and factibility. Cronbach’s Alfa was used to assess reliability 
and factor analysis to assess dimensionality. The EuroQol questionnaire and corre-
sponding Visual Analogue Scales were used for concurrent validity. RESULTS: A total 
of 200 students between the ages of 19–28 were participated in the study. Mean age 
was 22. The internal consistency coefﬁ cient (Cronbach’s alpha) of ADS was 0.92. 
Factor analysis of the scale revealed that it was composed of six factors with Eigen-
values >1.0, accounting for 74 % of the total variance. Correlations were moderate 
with EuroQol and VAS. CONCLUSIONS: The culturally adapted Alcohol Depen-
dence Scale has good validity and reliability. The instrument is likely to be suitable 
for the evaluation of alcohol dependence of people in Turkey.
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OBJECTIVES: In health economics, cost-effectiveness analyses are performed based 
on standardized established methods expressing outcomes in terms of costs per qual-
ity-adjusted life-year (QALY). In the ﬁ eld of care for criminal youth, interventions are 
increasingly drawn into the medical domain and towards reimbursement protocols so 
that a common cost-effectiveness measure becomes a necessity. However, cost-effec-
tiveness of these interventions has so far not been expressed in terms of cost per QALY, 
but in terms of clinical measures. The aim of this study is to explore the applicability 
of the QALY as effect measure of interventions for criminal youth. METHODS: The 
112 juvenile delinquents between 12 and 18 years included in this study were recruited 
at the start of Functional Family Therapy (FFT) from ﬁ ve mental health institutions 
in The Netherlands. Treatment efﬁ cacy was assessed using clinical outcome measures 
SDQ, YSR, CBCL, and PACS. Quality of life was measured using EuroQol EQ-5D. 
Data was analyzed to determine whether quality of life and clinical outcome measures 
show a signiﬁ cant correlation. Dutch population EQ-5D data was consulted to deter-
mine whether EQ-5D sufﬁ ciently captures differences between criminal and non-
criminal groups. RESULTS: Comparison between groups of criminal and non-criminal 
youths yielded no signiﬁ cant differences for juvenile delinquents or their parents. 
Correlation between several clinical outcome measures and EQ-5D scores of delin-
quent youths has been found suggesting that EQ-5D captures some differences in 
criminal behaviour. CONCLUSIONS: The study conﬁ rms the expected correlation 
between several classical forensic effect measures and general health economics out-
comes, but several aspects were not reﬂ ected by the QALY. Furthermore, the QALY 
measure insufﬁ ciently distinguishes between criminal and non criminal groups. We 
suggest further research before considering the application of the QALY as an effect 
measure for delinquent youths.
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BACKGROUND: High placebo response is observed in trials measuring subjective 
outcomes as in the case of GAD. This contributes to investigational drug failure owing 
to lack of differentiation between intervention and control group. Placebo run-in is 
frequently used to eliminate early responders however this has been criticised on the 
ground that it favours the active treatment. OBJECTIVES: To test the hypothesis that 
“The use of placebo run-in overestimates the treatment effect in placebo-controlled 
trials conducted in GAD”. METHODS: The Medline and EMBASE databases were 
searched to retrieve randomised, placebo-controlled trials conducted in adult GAD 
patients. Citations were screened on the basis of title and abstract and full text article 
of citations meeting eligibility criteria were sourced for detailed evaluation. Following 
this, citations reporting relevant outcomes were extracted using a pre-deﬁ ned extrac-
tion grid. Clinically relevant dichotomous outcomes: CGI-Improvement response, 
HAM-A response, and HAM-A remission were extracted. Considering heterogeneity 
among studies included, the random effects meta-analysis was performed in STATA 
9.0 using a standard meta-analysis approach. Results are presented as odds ratios with 
a 95% conﬁ dence interval. RESULTS: The literature search retrieved 1133 citations 
of which 41 were included following detailed evaluation (23 used placebo run-in 
phase). The point estimate for the relative treatment effect was similar (conﬁ dence 
interval overlap widely) irrespective of the use of placebo run-in phase (OR: 2.13 with 
run-in vs. 2.19 without run-in). Results were similar when individual outcomes were 
analyzed separately (HAM-A response OR: 2.17 vs. 2.14; CGI-I response OR: 2.20 
vs. 2.13; HAM-A remission OR: 1.98 vs. 2.05). CONCLUSIONS: Irrespective of 
outcomes considered, there was no statistically signiﬁ cant difference in the effect size 
between trials involving placebo run-in phase compared to those that did not. Our 
results do not support the hypothesis that the inclusion of placebo run-in overestimates 
the relative treatment effect in GAD. 
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OBJECTIVES: The study aimed to develop a standardized scale for co-morbidity 
assessment in Chronic Lymphocytic Leukaemia (CLL) patients to support physicians 
for selecting the optimal treatment according to the patient co-morbidity proﬁ le. 
METHODS: The co-morbidity scale was developed in four steps: a literature review 
to assess the existence of other scales and deﬁ ne the scale content; consensus meetings 
with ﬁ ve CLL experts to determine the content, format and weighting factor for each 
co-morbidity; a pilot study of 10 CLL patients to assess the scale feasibility; a meeting 
to agree the ﬁ nal version RESULTS: The literature review did not identify any existing 
scale but six papers related to assessment of CLL co-morbidities were selected. These 
allowed the initial selection of 21 diseases. In the expert meeting, the scale was reduced 
to 13 co-morbidities, with major impact on CLL treatment selection. Some additional 
variables (age, patient dependence and ECOG performance status) were added. Sub-
sequently, the ﬁ nal list of co-morbidities. variables and response options were agreed. 
The experts applied a weight factor to each co-morbidity, from 1 (minimal impor-
tance) to 3 (very important). a pilot study of 10 patients, using an electronic version 
of the scale, resulted in some changes but conﬁ rmed the scale’s feasibility. The ﬁ nal 
scale includes three sections. Part 1, the Functional Vital Scale, and a global assessment 
of the patient (not included in the global score). Part 2, the Co-morbidity scale, includ-
ing 11 co-morbidities weighted from 0 to 2 and scored from 0 (absence) to 2 (severe 
co-morbidity). Part 3, CLL alerts, is descriptive and includes the presence of splenec-
tomy and hypogammaglobulinemia. CONCLUSIONS: The co-morbidity scale is a 
tool to support the clinician in the selection of the optimal treatment for CLL patients. 
Further research is required to validate the scale and assess its beneﬁ ts.
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OBJECTIVES: Biologic treatment for severe forms of psoriasis proved to be effective 
and safety treatment in clinical trials. However, these drugs comprise a great ﬁ nancial 
burden. Therefore, we examined etanercept for treatment of severe forms of psoriasis 
in real clinical practice. METHODS: This was a prospective cohort non-interventional 
study of phase IV in real clinical practice which included 149 patients enrolled for 6 
months. Patients’ data were collected via electronic questionnaire. Clinical data (PASI 
score and BSA index), direct cost (inpatient and outpatient care, diagnostics, joint 
replacement etc.) and on QoL (expressed with EQ-5D and DLQI) were collected by 
